Search
Procept Biorobotics Corp
PRCTAdd to Watchlist
21.785USD
-1.685-7.18%
Market hours （ET）Quotes delayed by 15 min
1.22BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-7.28%
5 Days
+4.37%
1 Month
-21.89%
6 Months
-30.83%
Year to Date
-30.83%
1 Year
-61.53%
Key Figures
23.830Open
24.080High
735.85KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.32%Turnover Ratio
23.470Prev. Close
21.500Low
11.58MTurnover
LossP/E Static
3.20P/B
0.00%Div Yield TTM
-20.36%ROA
66.85052wk High
0.85Volume Ratio
-91.41MNet Profit
55.87MShares
-1.8301EPS TTM
0.85Beta
-27.81%ROE
19.35052wk Low
10.99%Amplitude
64.89%Gross Margin
1.22BMarket Cap
-3.26Reward/Risk
3.78%Risk Rate
TradingKey Stock Score of Procept Biorobotics Corp
Currency: USD Updated: 2026-07-01Key Insights
Procept Biorobotics Corp's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 49 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.54.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Procept Biorobotics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Procept Biorobotics Corp Highlights
StrengthsRisks
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 126.19% year-on-year.
Overvalued
The company’s latest PE is -12.82, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 65.01M shares, decreasing 1.54% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 1.07M shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
32.538
Target Price
+44.10%
Upside Space
Procept Biorobotics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Procept Biorobotics Corp Info
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Ticker SymbolPRCT
CompanyProcept Biorobotics Corp
CEOWood (Larry L)
Websitehttps://www.procept-biorobotics.com/
Related Instruments
+0.01%
+2.37%
+3.59%
+4.94%
+1.95%
-0.79%
+4.47%
+4.17%
+0.42%
+5.14%
+1.87%
+6.15%
+1.41%
+2.34%
-1.87%
+2.63%
+2.73%
-0.67%
-0.40%
-0.45%Popular Instruments
52641.400
+387.100 (+0.74%)
29287.300
-512.000 (-1.72%)
7457.700
-17.800 (-0.24%)
14749.000
-606.000 (-3.95%)
67976.000
-1509.000 (-2.17%)
6351.600
+76.200 (+1.21%)
67.984
+0.016 (+0.02%)
307.940
+13.560 (+4.61%)
193.690
-3.890 (-1.97%)
4117.220
+86.450 (+2.15%)
FAQs
What is the current price of Procept Biorobotics Corp (PRCT)?
The current price of Procept Biorobotics Corp (PRCT) is 23.47.
What is the symbol of Procept Biorobotics Corp?
The ticker symbol of Procept Biorobotics Corp is PRCT.
What is the 52-week high of Procept Biorobotics Corp?
The 52-week high of Procept Biorobotics Corp is 66.85.
What is the 52-week low of Procept Biorobotics Corp?
The 52-week low of Procept Biorobotics Corp is 19.35.
What is the market capitalization of Procept Biorobotics Corp?
The market capitalization of Procept Biorobotics Corp is 1.34B.
Is Procept Biorobotics Corp (PRCT) currently rated as Buy, Hold, or Sell?
According to analysts, Procept Biorobotics Corp (PRCT) has an overall rating of Buy, with a price target of 32.54.
What is the Earnings Per Share (EPS TTM) of Procept Biorobotics Corp (PRCT)?
The Earnings Per Share (EPS TTM) of Procept Biorobotics Corp (PRCT) is -1.72.